Companies › Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
4 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FDA018-ADC Antibody-drug conjugate | – | Phase 3 | Triple Negative Breast Cancer; Advanced/ Metastatic Solid Tumors | Jun 2027 |
| Hemoporfin Photodynamic therapy agent | – | Phase 2 | Port-wine Birthmarks | Jan 2027 |
| FZ-AD004 Antibody-drug conjugate | – | Phase 1 | Advanced and Metastatic Solid Tumor | Dec 2026 |
| FZ-AD005 | – | Phase 1 | Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma) | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05914545 | FZ-AD004 | Phase 1 | Advanced and Metastatic Solid Tumor | Oncology | Dec 2026 |
| NCT05171894 | Hemoporfin | Phase 2 | Port-wine Birthmarks | Other | Jan 2027 |
| NCT06519370 | FDA018-ADC | Phase 3 | Triple Negative Breast Cancer | Oncology | Jun 2027 |
| NCT06424665 | FZ-AD005 | Phase 1 | Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma) | Oncology | Dec 2027 |
| NCT05174637 | FDA018-ADC | Phase 1 | Advanced/ Metastatic Solid Tumors | Oncology | Dec 2029 |
No annotated target.
–
CStone Pharmaceuticals BioRay Pharmaceutical HUYABIO International Stemline Therapeutics Jiangsu Alphamab Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.